INDOUS vs MGEL: Stock Comparison
MANGALAM GLOBAL ENT is the larger company by market capitalisation. INDO US BIOTECH shows a lower P/E, lower leverage and a higher net margin, while MANGALAM GLOBAL ENT shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INDOUS leads 8; MGEL leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INDOUS | MGEL |
|---|---|---|
| Sector | Fast Moving Consumer Goods | Fast Moving Consumer Goods |
| Industry | Other Agricultural Products | Other Agricultural Products |
Price
| Metric | INDOUS | MGEL |
|---|---|---|
| Live Price | ₹78.29 | ₹15.52 |
| Day Change | 0.06% | -2.14% |
| Volume | 2,095 | 1.79 L |
| 52-Week High | ₹159 | ₹18.4 |
| 52-Week Low | ₹70 | ₹9.53 |
| Distance from 52W High | -50.76% | -15.65% |
Valuation
| Metric | INDOUS | MGEL |
|---|---|---|
| Market Cap | ₹160 Cr | ₹511 Cr |
| P/E Ratio | 0x | 10.31x |
| P/B Ratio | 0x | 1.96x |
| EPS | ₹1.51 | ₹0.26 |
| Book Value | ₹46.15 | ₹7.53 |
| Dividend Yield | 0% | 0.06% |
Growth
| Metric | INDOUS | MGEL |
|---|---|---|
| Revenue Growth (TTM YoY) | -22% | 24.92% |
| EPS Growth (TTM YoY) | -47.3% | -32.83% |
| Qtr Sales Growth | 26.75% | 19.28% |
| Qtr Profit Growth | 54.05% | 11.92% |
Profitability & Leverage
| Metric | INDOUS | MGEL |
|---|---|---|
| ROE | 14.18% | 17.49% |
| ROCE | 12.34% | 14.92% |
| Net Margin | 11.88% | 1.34% |
| Operating Margin | 14.64% | 2.58% |
| Debt to Equity | 0.4x | 0.59x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | INDOUS | MGEL |
|---|---|---|
| Promoter Holding | 68.29% | 72.38% |
| FII Holding | 0.01%▼ 0.17 pp | 0.09%▼ 0.09 pp |
| DII Holding | — | 0% |
| Public Holding | 31.7%▲ 0.17 pp | 27.53%▲ 0.09 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: INDO US BIOTECH and MANGALAM GLOBAL ENT.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.